AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

After a 2024 rebuff, AstraZeneca and Daiichi Sankyo’s star antibody drug conjugate Enhertu has been deemed cost effective for NHS use in HER2-low advanced breast cancer by England and Wales' drug value assessor.